Physician profile
David R Persaud
NPI 1609087527
$2,057.05
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $764 · 2021: $990 · 2022: $18.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $557.26 | 2019-2021 | |
| Glaxosmithkline, LLC. | $337.15 | 2019-2021 | |
| Lilly USA, LLC | $239.09 | 2020-2021 | |
| Boston Scientific Corporation | $115.16 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $85.69 | 2020-2021 | |
| Horizon Therapeutics Plc | $79.75 | 2020-2021 | |
| Indivior INC. | $74.84 | 2020-2021 | |
| Amarin Pharma, INC. | $57.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.68 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $52.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $44.29 | 2019-2021 | |
| Allergan, INC. | $42.56 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $37.99 | 2021 | |
| Abbott Laboratories | $37.95 | 2020-2021 | |
| Ibsa Pharma INC. | $35.99 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.20 | 2021 | |
| Pfizer INC. | $30.12 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.57 | 2021 | |
| Alkermes, INC. | $20.14 | 2019 | |
| Ironshore Pharmaceuticals INC. | $18.72 | 2019 | |
| Abbvie INC. | $15.86 | 2021 | |
| Merck Sharp & Dohme LLC | $15.40 | 2021 | |
| Roche Diagnostics Corporation | $15.00 | 2020 | |
| Eisai INC. | $13.74 | 2020 | |
| Amgen INC. | $13.42 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Persaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.